Healthcare provider profile · identity verified

Nenad Bugarija, MD

Allopathic & Osteopathic Physicians|Internal Medicine · SEVEN FIELDS, PA · NPI 1770646648

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Nenad Bugarija, MD received $136.87 in general payments during 2025 across 2 reported records.

Lilly USA, LLC accounted for 85.9% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 2 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Jardiance by this doctor in 2024.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Mounjaro by this doctor in 2024.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Trulicity by this doctor in 2024.

Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Ozempic by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$136.87

2 reported records · 2 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Lilly USA, LLC	Unresolved — no canonical attribution shown	$117.61	85.9%	1	2025
Novo Nordisk Inc	Unresolved — no canonical attribution shown	$19.26	14.1%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$136.87	2

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
ZEPBOUND Normalized: zepbound	Drug	Lilly USA, LLC	$117.61	1	2025
Source payment records 2025-04-22 · Lilly USA, LLC · $117.61 · Open Payments source
Ozempic Normalized: ozempic	Drug	Novo Nordisk Inc	$19.26	1	2025
Source payment records 2025-03-17 · Novo Nordisk Inc · $19.26 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
Ozempic ozempic	2025	Ozempic	2024	43 Beneficiary count suppressed	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	JARDIANCE open payments reported associated product	CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557	Jardiance · 2024 Exact normalized brand match · 1 Part D row	119	31
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	MOUNJARO open payments reported associated product	CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455	Mounjaro · 2024 Exact normalized brand match · 1 Part D row	31	suppressed by CMS
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	TRULICITY open payments reported associated product	CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601	Trulicity · 2024 Exact normalized brand match · 1 Part D row	135	19
Novo Nordisk Inc Exact reporting entity; no affiliate inference	2025	Ozempic open payments reported associated product	CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076	Ozempic · 2024 Exact normalized brand match · 1 Part D row	43	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	735	217
Levothyroxine Sodium	Levothyroxine Sodium	674	181
Amlodipine Besylate	Amlodipine Besylate	391	120
Pantoprazole Sodium	Pantoprazole Sodium	321	101
Rosuvastatin Calcium	Rosuvastatin Calcium	309	112
Carvedilol	Carvedilol	295	82
Losartan Potassium	Losartan Potassium	287	93
Eliquis	Apixaban	280	53
Gabapentin	Gabapentin	180	52
Metformin Hcl	Metformin Hcl	176	52
Omeprazole	Omeprazole	174	52
Valsartan	Valsartan	172	58
Hydrochlorothiazide	Hydrochlorothiazide	156	52
Tamsulosin Hcl	Tamsulosin Hcl	153	51
Lisinopril	Lisinopril	152	54
Pravastatin Sodium	Pravastatin Sodium	141	43
Furosemide	Furosemide	138	41
Metoprolol Succinate	Metoprolol Succinate	136	39
Potassium Chloride	Potassium Chloride	136	41
Trulicity	Dulaglutide	135	19
Montelukast Sodium	Montelukast Sodium	132	46
Metoprolol Tartrate	Metoprolol Tartrate	129	45
Olmesartan Medoxomil	Olmesartan Medoxomil	121	41
Ezetimibe	Ezetimibe	119	40
Jardiance	Empagliflozin	119	31
Ibandronate Sodium	Ibandronate Sodium	118	22
Simvastatin	Simvastatin	111	33
Synthroid	Levothyroxine Sodium	104	30
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	102	30
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	101	28
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	100	25
Tradjenta	Linagliptin	99	28
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	99	34
Breo Ellipta	Fluticasone/Vilanterol	98	25
Fluticasone Propionate	Fluticasone Propionate	96	35
Alprazolam	Alprazolam	95	34
Escitalopram Oxalate	Escitalopram Oxalate	94	30
Trazodone Hcl	Trazodone Hcl	93	30
Allopurinol	Allopurinol	90	30
Finasteride	Finasteride	90	27
Sertraline Hcl	Sertraline Hcl	89	23
Meloxicam	Meloxicam	87	28
Xarelto	Rivaroxaban	86	17
Venlafaxine Hcl Er	Venlafaxine Hcl	85	27
Irbesartan	Irbesartan	80	21
Celecoxib	Celecoxib	79	41
Donepezil Hcl	Donepezil Hcl	79	28
Duloxetine Hcl	Duloxetine Hcl	75	25
Prednisone	Prednisone	75	43
Metformin Hcl Er	Metformin Hcl	69	25
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	67	18
Zolpidem Tartrate	Zolpidem Tartrate	65	18
Famotidine	Famotidine	64	20
Albuterol Sulfate Hfa	Albuterol Sulfate	63	33
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	63	20
Mirtazapine	Mirtazapine	62	17
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	61	24
Atenolol	Atenolol	55	16
Bupropion Xl	Bupropion Hcl	53	17
Methylprednisolone	Methylprednisolone	53	48
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	52	17
Spironolactone	Spironolactone	46	21
Alendronate Sodium	Alendronate Sodium	45	suppressed
Lorazepam	Lorazepam	45	21
Ozempic	Semaglutide	43	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	42	suppressed
Pregabalin	Pregabalin	40	suppressed
Digoxin	Digoxin	39	suppressed
Solifenacin Succinate	Solifenacin Succinate	36	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	35	suppressed
Creon	Lipase/Protease/Amylase	35	suppressed
Paroxetine Hcl	Paroxetine Hcl	35	suppressed
Zaleplon	Zaleplon	35	suppressed
Labetalol Hcl	Labetalol Hcl	34	suppressed
Unithroid	Levothyroxine Sodium	34	suppressed
Citalopram Hbr	Citalopram Hydrobromide	33	12
Clonidine Hcl	Clonidine Hcl	33	suppressed
Clopidogrel	Clopidogrel Bisulfate	33	13
Memantine Hcl	Memantine Hcl	33	suppressed
Mounjaro	Tirzepatide	31	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	31	suppressed
Hydralazine Hcl	Hydralazine Hcl	30	suppressed
Amlodipine-Olmesartan	Amlodipine Bes/Olmesartan Med	29	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	29	27
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	29	13
Triamcinolone Acetonide	Triamcinolone Acetonide	29	11
Warfarin Sodium	Warfarin Sodium	29	suppressed
Glipizide Er	Glipizide	28	12
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	28	11
Ropinirole Hcl	Ropinirole Hcl	28	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	27	14
Metolazone	Metolazone	27	suppressed
Colchicine	Colchicine	26	11
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	26	suppressed
Meclizine Hcl	Meclizine Hcl	26	suppressed
Tiotropium Bromide	Tiotropium Bromide	26	suppressed
Azithromycin	Azithromycin	25	25
Clonazepam	Clonazepam	25	11
Levetiracetam	Levetiracetam	25	suppressed
Ondansetron Hcl	Ondansetron Hcl	25	13
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	24	suppressed
Propranolol Hcl Er	Propranolol Hcl	24	suppressed
Raloxifene Hcl	Raloxifene Hcl	24	suppressed
Tramadol Hcl	Tramadol Hcl	24	11
Doxycycline Hyclate	Doxycycline Hyclate	23	22
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	23	suppressed
Humalog Kwikpen U-100	Insulin Lispro	22	suppressed
Spironolactone-Hctz	Spironolact/Hydrochlorothiazid	22	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	21	21
Clonidine	Clonidine	21	suppressed
Eszopiclone	Eszopiclone	21	suppressed
Oxycodone Hcl	Oxycodone Hcl	21	12
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	21	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	20	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	20	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	19	suppressed
Fenofibrate	Fenofibrate,micronized	19	suppressed
Lidocaine	Lidocaine	19	suppressed
Morphine Sulfate Er	Morphine Sulfate	19	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	19	suppressed
Dilt-Xr	Diltiazem Hcl	18	suppressed
Ibuprofen	Ibuprofen	18	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	18	suppressed
Baclofen	Baclofen	17	suppressed
Fenofibrate	Fenofibrate	17	suppressed
Metronidazole	Metronidazole	17	suppressed
Sucralfate	Sucralfate	17	suppressed
Amlodipine-Valsartan	Amlodipine Besylate/Valsartan	16	suppressed
Propranolol Hcl	Propranolol Hcl	16	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	16	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	15	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	14	suppressed
Linzess	Linaclotide	14	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	14	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	14	14
Valacyclovir	Valacyclovir Hcl	14	suppressed
Ventolin Hfa	Albuterol Sulfate	14	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	13	suppressed
Doxepin Hcl	Doxepin Hcl	13	suppressed
Exelon	Rivastigmine	13	suppressed
Jantoven	Warfarin Sodium	13	suppressed
Mesalamine	Mesalamine	13	suppressed
Myrbetriq	Mirabegron	13	suppressed
Aimovig Autoinjector	Erenumab-Aooe	12	suppressed
Azelastine Hcl	Azelastine Hcl	12	suppressed
Cyanocobalamin Injection	Cyanocobalamin (Vitamin B-12)	12	suppressed
Demeclocycline Hcl	Demeclocycline Hcl	12	suppressed
Dutasteride	Dutasteride	12	suppressed
Januvia	Sitagliptin Phosphate	12	suppressed
Klor-Con M20	Potassium Chloride	12	suppressed
Minoxidil	Minoxidil	12	suppressed
Nifedipine Er	Nifedipine	12	suppressed
Telmisartan	Telmisartan	12	suppressed
Verapamil Er	Verapamil Hcl	12	suppressed
Brilinta	Ticagrelor	11	suppressed
Buspirone Hcl	Buspirone Hcl	11	suppressed
Clobetasol Propionate	Clobetasol Propionate	11	suppressed
Diclofenac Sodium	Diclofenac Sodium	11	suppressed
Dilantin	Phenytoin Sodium Extended	11	suppressed
Glatiramer Acetate	Glatiramer Acetate	11	suppressed
Ipratropium Bromide	Ipratropium Bromide	11	suppressed
Lacosamide	Lacosamide	11	suppressed
Olmesartan-Amlodipine-Hctz	Olmesartan/Amlodipin/Hcthiazid	11	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	11	suppressed
Tadalafil	Tadalafil	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$136.87 · 2 records	Lilly USA, LLC	Ozempic, ZEPBOUND	4	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Ozempic play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error